うつ病のためのTCM健康維持 (TCMHPFD)
うつ病に対する漢方薬の健康維持介入:パイロット無作為対照試験
This study aims to evaluate the feasibility and preliminary effects of Traditional Chinese Medicine (TCM) health preservation for depression on depressive symptoms reduction and other health-related outcomes among Hong Kong Chinese adults with depression. Participants in intervention group will receive TCM health preservation course for six weeks (6 sessions, 2 hours each) and practice TCM health preservation during the 6-week follow-up period. Participants in the control group (waitlist control) will receive usual care. After the follow-up assessment, TCM health preservation courses for depression will be provided to them for compensation.
調査の概要
状態
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Hong Kong、香港
- School of Nursing, the Hong Kong Polytechnic University
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Hong Kong Chinese adults aged 18-years-old to 65-years-old;
- diagnosed with moderate level of depression (a score of 10~20), evaluated by the Patient Health Questionnaire-9 (PHQ-9);
- can communicate in spoken Cantonese and written Chinese;
- willing to provide written informed consent and be able to adhere to the study protocol.
Exclusion Criteria:
- being pregnant or during the lactation, or plan to get pregnant;
- new onset or change of antidepressant medication or dosage in the last 3 months;
- PHQ-9 score≥20, meaning a severe level of depression;
- with a previous or present diagnosis of psychotic disorders as screened by the Chinese version of the Structured Clinical Interview for DSM-IV;
- the score of Hong Kong Montreal Cognitive Assessment less than 22;
- significant suicidal risk as rated by the Hamilton Depression Rating Scale item on suicide (score ≥3);
- with diagnosis of illness which can interfere the individuals to participate or adhere to the modified lifestyle;
- with diagnosis of medical conditions, which are not suitable to modify diet or do physical activities recommended by physicians;
- joining in another clinical trial during the study period;
- with any major medical condition that causes depression based on the judgement of the investigator.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:traditional Chinese medicine health preservation group
The participants in the traditional Chinese medicine health preservation group will attend six traditional Chinese medicine health preservation courses (2h each per one, for 6 weeks) to learn and experience traditional Chinese medicine health preservation from a registered traditional Chinese medicine practitioner in a classroom at the School Nursing, the Hong Kong Polytechnic University. Each class will be conducted in a small group of 4 to 6 participants to enhance interaction and ensure the quality of teaching. Participants will then practice traditional Chinese medicine health preservation at home for 6 weeks. |
The traditional Chinese medicine health preservation intervention for depression was developed based on a previous systematic review and meta-analysis of Traditional Chinese medicine based integrated health interventions for depression, traditional Chinese medicine health preservation textbooks, clinical practice guidelines related to traditional Chinese medicine health preservation and traditional Chinese medicine treatment for depression. The content and structure of traditional Chinese medicine health preservation for depression was achieved among Hong Kong traditional Chinese medicine experts via a Delphi study. Usual care |
|
介入なし:Waitlist control group
Participants in the waitlist control group will receive usual care during the 6-week waitlist period of intervention, and 6-week waitlist period of follow-up. After the follow-up assessment, they will be provided an equivalent traditional Chinese medicine health preservation for depression. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in the Patient Health Questionnaire (PHQ-9)
時間枠:Time Frame: Baseline, week 2, week 4, week 6, week 8, week 12
|
The PHQ-9, a self-rated questionnaire to assess the presence and severity of depressive symptoms of an individual during the last 2 weeks on a scale of 0 (not at all) to 3 (nearly every day), with a total score ranging from 0 to 27. A higher score indicates a higher severity of depression symptoms. |
Time Frame: Baseline, week 2, week 4, week 6, week 8, week 12
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in the Generalized Anxiety Disorder-7 (GAD-7)
時間枠:Time Frame: Baseline, week 2, week 4, week 6, week 8, week 12
|
The GAD-7 is a four-point Likert scale for identifying probable cases of GAD and assess the severity of symptoms of GAD for the past 2 weeks. The total score of GAD-7 varies from 0 to 21, and responses include "nearly every day," "more than half the days," "several days", and "not at all". The cutoff point of 5, 10, and 15 of GAD-7 might be interpreted as showing mild, moderate, and severe levels of anxiety. Higher scores indicate more severe GAD symptoms. |
Time Frame: Baseline, week 2, week 4, week 6, week 8, week 12
|
|
Change in the Perceived Stress Scale (PSS-10)
時間枠:Time Frame: Baseline, week 2, week 4, week 6, week 8, week 12
|
The PSS-10 is a 10-item scale that is often used for measuring perceived psychological stress. Each item is rated on a 5-point Liket scale during the past month, referring to "4" as "very often" and "0" as never. The total score changes from 0 to 40, with a higher score meaning a higher perceived psychological stress level. |
Time Frame: Baseline, week 2, week 4, week 6, week 8, week 12
|
|
Change in the Insomnia Severity Index (ISI)
時間枠:Time Frame: Baseline, week 2, week 4, week 6, week 8, week 12
|
The ISI is a seven-item self-rating scale to assess the severity of insomnia, distress, and functional impairment associated with insomnia on a 5-point Likert scale. The score of each item of ISI ranges from 0 (no problem) to 4 (very severe problem), and the total score is interpreted as below: absence of insomnia as 0 to 7, sub-threshold insomnia as 8 to14, moderate insomnia as 15 to 21, and severe insomnia as 22 to 28. |
Time Frame: Baseline, week 2, week 4, week 6, week 8, week 12
|
|
Change in the Fatigue Assessment Scale (FAS)
時間枠:Time Frame: Baseline, week 2, week 4, week 6, week 8, week 12
|
The FAS is a 10-item scale that evaluates symptoms of chronic fatigue with a five-point Likert-type scale, which ranges from 1 ("never") to 5 ("always"). A higher score means greater fatigue severity. The total score ranges from 10 to 50. A total FAS score < 22 means no fatigue, a score≥ 22 refers to fatigue. |
Time Frame: Baseline, week 2, week 4, week 6, week 8, week 12
|
|
Change in the Short-Form (six-dimension) Health Survey (SF-6D)
時間枠:Time Frame: Baseline, week 6, week 8, week 12
|
The SF-6D covers six domains using a scale of 1 to 6 to evaluate participants' general health and quality of life. Higher scores indicate better health status. |
Time Frame: Baseline, week 6, week 8, week 12
|
|
Change in the General Self-Efficacy Scale (GSE)
時間枠:Time Frame: Baseline, week 2, week 4, week 6, week 8, week 12
|
The GSE scale is a four-point Likert scale with ten items appropriate for evaluating an individual's self-efficacy. It is scored ranging from 1 point to 4 points, referring to "not at all true" to "exactly true" and the total score varied from 10 to 40. A higher score shows a more satisfactory self-efficacy. |
Time Frame: Baseline, week 2, week 4, week 6, week 8, week 12
|
|
Change in the Health-Promoting Lifestyle Profile II (HPLP II)
時間枠:Time Frame: Baseline, week 4, week 6, week 8, week 12
|
The HPLP II is a scale with 52 items and 6 domains for measuring health-promoting behavior, defined as a multidimensional pattern of self-initiated perceptions and actions that serve to maintain or increase the level of self-actualization, wellness, and fulfillment of a person. The total scores of HPLP-II varies from 52 to 208. Higher HPLP II score denotes better level of health-promoting lifestyle. |
Time Frame: Baseline, week 4, week 6, week 8, week 12
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in the Credibility/ Expectancy Questionnaire (CEQ)
時間枠:Time Frame: Baseline, week 6
|
The CEQ is a self-reported scale with 6 items and two subscales of treatment credibility and outcome expectancy to measure the participants' treatment credibility and outcome expectancy for improvement. The final scoring of the CEQ is computed by the sum of the items composing each subscale, with a higher quotation referring to higher treatment credibility and outcome expectation. The CEQ taps on participants' affective and cognitive evaluations of treatment satisfaction, credibility, and expectation. The subscale of credibility assesses beliefs about the treatment strength. The expectancy subscale assesses how participants perceive their symptoms will improve during the intervention period. |
Time Frame: Baseline, week 6
|
協力者と研究者
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- TCMHPFD
- No.21B2/004A (その他の助成金/資金番号:the Chinese Medicine Development Fund, Hong Kong Special Administrative Region, China)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The individual participant data will be available when the study has been published. The individual participant data will be available upon request.
IPD 共有時間枠
No time restriction for the data availability
IPD 共有アクセス基準
The individual participant data will be available upon request
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。